Introduction
We are in a challenging era of increasing use of coronary stenting for coronary artery disease (CAD) in the UK,1 in conjunction with a growing population of patients with atrial fibrillation (AF) predominantly driven by age, hypertension, obesity and diabetes.2
Inevitably, these two common diseases, with similar risk factors, occur simultaneously in a significant proportion (5 to 8%) of patients undergoing revascularisation.3-5 This equates to an estimated 4,500 to 7,200 patients in the UK population, based upon British Cardiovascular Intervention Society (BCIS) data in 2014.1
Atrial phase thrombus has a stasis and fibrin drive,